27
September
2022


Share on networks

The Swiss group Novartis, one of the world leaders in biomedical innovation in cardiology, oncology, immunology, neuroscience, ophthalmology and respiratory areas, will invest 77.4 million euros to expand its production activity in Spain. Of the total investment, 63 million will go to the Barcelona plant.

This centre will increase its production capacity by 150% and will become one of the group’s two antibiotic production hubs for the whole of Spain. This increase in production will generate some 84 new jobs.

INVESTMENT OBJECTIVES

According to Novartis, an investment of close to 100 million euros in R&D&I projects facilitated 287 clinical trials in Spain, involving 7,753 patients.

Marie France Tschudin, global president of the innovative medicines division, defended to the minister and head of the Moncloa economy the need for collaboration between companies and public health systems in order to improve healthcare and thus guarantee patients’ access to the most innovative treatments.

Tschudin stressed that the Swiss company will seek ways of collaborating with the public health system in the field of cardiovascular disease, which has the highest mortality rate.

Share on networks

Related news

Saló Nàutic de Barcelona

News

Successful Saló Nàutic closes with 50.000 visitors and more than 700 vessels

Universitat de Barcelona

News

Barcelona is home to 3 of the best universities in the world according to the THE Ranking

Barcelona Cable Landing Station

News

By the end of this year the Barcelona Cable Landing Station will be ready to receive the first submarine cables.